Search
forLearn
5 / 801 resultslearn nonspecific group of glycoproteins
learn multipeptides
learn ascorbic acid
learn HYDROXYPROPYLAMMONIUM GLUCONATE
Research
5 / 1000+ results
research Development, Characterization, and Use of a Fetal Skin Cell Bank for Tissue Engineering in Wound Healing
Fetal skin cells from a cell bank heal wounds faster and with less scarring than adult cells.
research Manifestaciones Cutáneas en el Paciente Inmunocomprometido: Una Revisión Narrativa
Early recognition of skin issues in immunocompromised patients is crucial for better outcomes.
research Immunodeficiency Disorders
People with primary immunodeficiencies often have frequent, severe, or unusual infections and may need special tests and management strategies.
research 067 BELCOMID: BELgian Cohort study of COVID-19 in Immune Mediated Inflammatory Diseases
COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.
research Varicella Recurrence Complicated by Pneumonia After Liver Transplantation for APECED
A liver transplant patient with APECED had a rare VZV recurrence and pneumonia, treated successfully, but later died from other infections.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Pre-mixed RU58841 in the KB solution vs PG solution?
community Treating my DUPA via controlling inflammation
The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.
community PP405 (Non) Update - Feb 2025
The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.
community Update for PP405 - phase 2b underway
PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.